A groundbreaking medical advancement promises to revolutionize the diagnosis of cystic fibrosis (CF), potentially saving countless lives by making testing more accessible to infants globally. A study published in Digital Medicine reveals that a pair of wearable, flexible stickers can accurately diagnose the genetic disorder, offering a portable and low-cost alternative to the complex laboratory procedures currently required.
Cystic fibrosis is a life-altering condition that causes severe digestive and respiratory complications. While the projected median survival age in the United States currently stands at 66 years with proper care, children who remain undiagnosed often face a life expectancy of less than five years. Experts estimate that nearly half of all individuals living with CF worldwide have yet to receive a formal diagnosis.
“This is critical, since earlier diagnosis is linked to better health outcomes and longer life,” said Dr. Susanna McColley, a CF expert at the Ann & Robert H. Lurie Children’s Hospital of Chicago and professor of pediatrics at Northwestern University Feinberg School of Medicine.
The current standard for diagnosing CF is highly specialized, requiring children to be brought to accredited cystic fibrosis centers at large hospitals. This creates a significant barrier for families living in rural areas or those in lower-income countries where such sophisticated infrastructure is unavailable.
The new technology, dubbed “CF SWIFT,” was developed by a team at Northwestern University’s Querrey Simpson Institute for Bioelectronics. The system consists of two soft, skin-safe stickers. The first uses a small chemical dose and a button battery to painlessly stimulate sweat production. The second sticker is then applied to collect the sweat. Once the collection is complete, a smartphone app analyzes the chloride content by measuring changes in color density within the sticker. The entire diagnostic process is completed in under an hour.
In the study, researchers tested 55 participants—ranging from infants to young adults—comparing the performance of the stickers against traditional lab methods. The results showed a high correlation, confirming the device’s reliability.
“The new CF SWIFT device is a complete self-contained system,” said co-senior study author John Rogers, highlighting that this iteration is a significant advancement over previous prototypes.
Despite these promising results, the research team emphasized that more work is needed before the stickers reach the market. The next phase involves a multicenter study focusing specifically on younger infants, as most diagnostic sweat tests are currently performed during a baby’s first weeks of life. Following these trials, the technology will require formal FDA approval.
If cleared for widespread clinical use, these simple, affordable stickers could bridge the massive gap in global health equity, ensuring that children—regardless of their geography—can receive the life-saving treatments they require long before the disease causes irreversible damage.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
